Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009;11(5):243.
doi: 10.1186/ar2729. Epub 2009 Oct 14.

Toll-like receptors and NOD-like receptors in rheumatic diseases

Affiliations
Review

Toll-like receptors and NOD-like receptors in rheumatic diseases

William J McCormack et al. Arthritis Res Ther. 2009.

Abstract

The past 10 years have seen the description of families of receptors that drive proinflammatory cytokine production in infection and tissue injury. Two major classes have been examined in the context of inflammatory joint disease--the Toll-like receptors (TLRs) and NOD-like receptors (NLRs). TLRs such as TLR2 and TLR4 are being implicated in the pathology of rheumatoid arthritis, ankylosing spondylitis, lyme arthritis and osteoarthritis. Nalp3 has been identified as a key NLR for IL-1beta production and has been shown to have a particular role in gout. These findings present new therapeutic opportunities, possibly allowing for the replacement of biologics with small molecule inhibitors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Signaling through pathogen-associated and damage-associated molecular patterns drives chronic inflammation in diseases like rheumatoid arthritis. Bacterial DNA, peptidoglycans, muramyl dipeptide and viral molecules have been found in arthritic joints. These microbial pathogen-associated molecular patterns (PAMPs) can drive inflammation through the membrane-bound (Toll-like receptor (TLR)) and cytosolic (NOD-like receptor (NLR)) pattern recognition receptors (PRRs). The resulting release in inflammatory cytokines can drive the damage of host tissue releasing damage-associated molecular patterns (DAMPs), such as high-mobility group box protein 1, GP96, heat shock proteins and ATP, which also activate both types of PRR resulting in a vicious cycle of inflammation.
Figure 2
Figure 2
Treating spontaneous arthritis with a TLR4 antagonist suppresses the clinical and histological characteristics of arthritis. Abdollahi-Roodsaz and colleagues have recently shown that treating collagen-induced arthritis (left-hand side) with a TLR4 antagonist suppresses the clinical and histological characteristics of arthritis (right-hand side). Histological images of knee joints are shown, stained with hematoxylin and eosin. Arrow indicates inflammatory cell influx and chondrocyte cell death. Image taken from [21]. Reproduced with permission of John Wiley and Sons.

References

    1. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev. 2008;226:10–18. doi: 10.1111/j.1600-065X.2008.00701.x. - DOI - PubMed
    1. Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG, Lee H, Lee JO. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell. 2007;130:1071–1082. doi: 10.1016/j.cell.2007.09.008. - DOI - PubMed
    1. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ, Lee JO. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007;130:906–917. doi: 10.1016/j.cell.2007.08.002. - DOI - PubMed
    1. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. 2000;1:398–401. doi: 10.1038/80833. - DOI - PubMed
    1. Awomoyi AA, Rallabhandi P, Pollin TI, Lorenz E, Sztein MB, Boukhvalova MS, Hemming VG, Blanco JC, Vogel SN. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol. 2007;179:3171–3177. - PubMed

Publication types

MeSH terms

Substances